Edwards Lifesciences, Medtronic Lead Tissue Heart Valve Market Fueled by Replacement Procedures
Unit Sales Are a Primary Driver of Growth in the U.S. Market for Tissue Heart Valves; Growth in These Unit Sales Is Powered by the Continued Shift in Tissue Valve Procedure and Material Preference

/EINPresswire.com/ -- VANCOUVER, BC--(Marketwired - May 30, 2016) - According to a new series of reports on the U.S. market for cardiac surgery and heart valve devices by iData Research (www.idataresearch.com), growth in the U.S. tissue heart valve market is primarily fueled by unit sales and a growing number of heart valve replacement procedures, as well as the continued shift in preference for tissue valves over mechanical valves. Technological improvements helping to increase durability of tissue valves have further helped to fuel growth.
The majority of tissue valve replacement procedures performed in the U.S. is for the aortic valve. Mitral valve replacements accounted for approximately 22% of all tissue valve procedures performed in 2015. The share of total tissue valve replacement procedures represented by mitral valves is expected to increase over the forecast period as the penetration rate of transcatheter aortic valve replacement procedures increases and the treatment of mitral valve defects shifts from repair to replacement.
The U.S. market for tissue heart valves is segmented by stented tissue heart valves and stentless tissue heart valves. The stentless valves have some inherent advantages over stented valves. Stentless valves better mimic the natural physiological functioning of heart valves, because absence of the stent allows for unimpeded, natural blood flow through the valve, reducing stress on the surrounding heart tissue and increasing the durability of the valve itself. Despite these benefits, the difficulty of the stentless valve implantation procedure is expected to cause this segment to decline over the forecast period. Growth in the unit sales of stented tissue heart valves is expected to propel an increase in the value of the stented tissue heart valve segment.
Most tissue heart valves use xenograft tissue. However, a small percentage of tissue heart valve unit sales are allograft valves. The unit sales of the allograft heart valves are limited by the availability of tissue donors.
"Tissue valve market growth is expected to decelerate over the forecast period as the market is reaching maturity," explains Dr. Kamran Zamanian, CEO of iData. "The increasing penetration rate of transcatheter aortic valve implantation devices will also aid in decelerating the growth in unit sales of tissue heart valves."
Edwards Lifesciences is the leading competitor in the U.S. market for tissue heart valves. Edwards Lifesciences offers a diverse tissue valve product line. The company's best known products include the Carpentier-Edwards PERIMOUNT
St. Jude Medical, currently in the process of being acquired by Abbott Laboratories, is the third leading competitor and has traditionally focused on the mechanical valve market, in which it is the leader, but held a sizeable share of the tissue heart valve market. St. Jude formerly generated most of its tissue valve revenue from its Toronto SPV
For Further Information
More on the tissue heart valve market in the United States can be found in a report suite published by iData Research entitled the U.S. Market for Cardiac Surgery and Heart Valve Devices. The suite covers reports on the following markets: Tissue Heart Valves, Mechanical Heart Valves, Annuloplasty Repair Devices, Transcatheter Heart Valve Repair Devices, Transcatheter Heart Valve Implantations, On-pump Coronary Artery Bypass Devices, Off-pump Coronary Artery Bypass Devices, Endoscopic Vessel Harvesting Market, Anastomosis Assist Devices, Transmyocardial Revascularization Devices, Ventricular Assist Devices, Intra-aortic Balloon Pump Devices, Artificial Heart Replacement Devices, Patent Foramen Ovale Devices, Atrial & Ventricular Septal Defect Devices, and Left Atrial Appendage Closure Devices.
The iData series on cardiac surgery covers the U.S., China, Japan, South Korea, Australia, and 15 countries in Europe encompassing Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about cardiac surgery market data or procedure data, register online or email us at info@idataresearch.net for a US Market for Cardiac Surgery and Heart Valve Devices report series brochure and synopsis.
About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.
Contact Info
Marvin Cidamon
Marketing Coordinator
iData Research Inc.
604-266-6933 Ext. 205
marvinc@idataresearch.net
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
